Light-Controlled Antibacterial Peptide via Azobenzene Cyclodextrin

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antibacterial peptides face challenges with poor selectivity, low antibacterial efficiency, and side effects on healthy cells, and the development of light-responsive "intelligent antibacterial peptides" is slow due to complex preparation processes and high costs, limiting their application.

Innovation Solution

A light-controlled antibacterial agent composed of linear cationic oligopeptide and multi-arm β-cyclodextrin is developed, utilizing azobenzene for photoisomerization to regulate antibacterial activity through "host-guest" recognition, forming cross-linked aggregates that enhance bonding with bacterial cell membranes and can be controlled in time and space with light irradiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cyclic peptides are used to achieve light-responsive antibacterial activity, then antibacterial properties can be regulated with light, but the preparation process becomes complex, yield decreases, and cost increases

Engineering Contradiction:

Improvelight-responsive antibacterial activityVSAvoidpreparation process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces expensive cyclic peptides with cheap linear oligopeptides that can be easily synthesized. The linear oligopeptides achieve light-responsive antibacterial activity through azobenzene photoisomerization without requiring complex cyclic structures, thereby reducing preparation complexity and cost while maintaining reliability

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the molecular structure parameter from cyclic to linear oligopeptide configuration. This parameter change simplifies the preparation process while maintaining light-responsive antibacterial activity through the incorporation of azobenzene groups that undergo photoisomerization to regulate antibacterial properties

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If traditional antibacterial peptides are used to achieve broad antibacterial spectrum, then both gram-negative and gram-positive bacteria can be targeted, but selectivity to healthy cells deteriorates causing side effects

Engineering Contradiction:

Improveantibacterial spectrumVSAvoidside effects on healthy cells

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces dynamic light control to regulate antibacterial activity. The azobenzene groups in the linear oligopeptides undergo photoisomerization upon light irradiation, dynamically switching between active and inactive states. This allows selective activation of antibacterial activity only when and where needed, reducing side effects on healthy cells while maintaining broad antibacterial spectrum

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent replaces the static mechanical interaction of traditional antibacterial peptides with light-controlled optical regulation. The azobenzene photoisomerization mechanism substitutes for constant antibacterial activity, allowing spatial and temporal control to distinguish between pathogenic bacteria and healthy cells, thereby reducing harmful side effects

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of manufacture

If linear oligopeptides are used to achieve easy synthesis and batch preparation, then manufacturing cost decreases, but light-responsive antibacterial activity has not been realized

Engineering Contradiction:

Improvesynthesis ease and batch preparationVSAvoidlight-responsive antibacterial activity

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent merges the simplicity of linear oligopeptide synthesis with light-responsive functionality by incorporating azobenzene groups into the linear structure. This combination maintains the ease of batch preparation while achieving light-controlled antibacterial activity, resolving the contradiction between manufacturability and functional reliability

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent creates a composite material system combining linear oligopeptide backbone with azobenzene photoresponsive groups. This composite structure retains the synthesis advantages of linear peptides while adding light-responsive antibacterial activity, achieving both ease of manufacture and functional reliability

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20210060165A1Light-Controlled Antibacterial Agent Composed of Linear Cationic Oligopeptide and Multi-arm B-Cyclodextrin

Publication Date: 2021.03.04 JILIN UNIVERSITY

AI summary

A light-controlled antibacterial agent composed of linear cationic oligopeptide and multi-arm β-cyclodextrin that regulates antibacterial activity with light, belongs to the technical field of antibacterial materials. The light-controlled antibacterial agent with light response composed of linear cationic oligopeptide and multi-Arm β-cyclodextrin of the present invention is cross-linked aggregates formed from linear cationic oligopeptide containing azobenzene and multi-arm cyclodextrin by “host-guest” recognition. The linear cationic oligopeptide and the multi-arm β-cyclodextrin have significantly different antibacterial activities in two states of aggregation and deaggregation. The present invention uses the photoisomerization property of azobenzene conformation in the linear cationic oligopeptide to regulate the combination and dissociation of the “host-guest” recognition between azobenzene and cyclodextrin and to control the formation and disintegration of cross-linked aggregates so as to regulate the antibacterial activity of linear cationic oligopeptide with light.